← Back to Patent Explorer
US5288629A Expired / Lapsed US ⏱️ 0.0 years remaining

DNA sequence encoding Factor VII with an amino acid substitution at Avg-152

Assignee: Novo Nordisk Health Care AG
•
Filing: 1992-09-21
•
Granted: 1994-02-22
•
Expires: 2012-09-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Factor VII of the coagulation cascade is modified to act as an anticoagulant. Amino acid modifications are employed to produce a modified Factor VII having a substantially reduced susceptibility to activation by enzymes which typically activate wild-type Factor VII. The modified Factor VII is able to compete with wild-type Factor VII and/or VIIa for binding tissue factor, inhibiting clotting activity. As the modified Factor VII acts specifically to interrupt the coagulation cascade, pharmaceutical compositions of modified Factor VII may be administered in place of, or in conjunction with lower doses of, conventional anticoagulant therapies.

Inventors

  • 👤 Kathleen L. Berkner

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 18:18
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6437; A; A61; A61P; A61P7/00; A61P7/02; C12Y; C12Y304/00; C12Y304/21; C12Y304/21021; A61K; A61K38/00

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 76 words
A polynucleotide molecule comprising two operatively linked sequence coding regions encoding, respectively, a pre-pro peptide and a gla domain of a vitamin K-dependent plasma protein, and a gla domain-less Factor VII having an amino acid substitution in the activation region, wherein said polynucleotide encodes a modified Factor VII molecule that is resistant to activation by plasma Factor Xa, as compared to wild-type Factor VIIa, and is capable of inhibiting the clotting activity of wild-type Factor VIIa.
Claim 2
Dependent Claim 76 words
A polynucleotide molecule comprising two operatively linked sequence coding regions encoding, respectively, a pre-pro peptide and a gla domain of a vitamin K-dependent plasma protein, and a gla domain-less Factor VII having an amino acid substitution in the activation region, wherein said polynucleotide encodes a modified Factor VII molecule that is resistant to activation by plasma Factor Xa, as compared to wild-type Factor VIIa, and is capable of inhibiting the clotting activity of wild-type Factor VIIa.
Claim 3
Dependent Claim 34 words
The polynucleotide molecule according to claim 1, wherein the amino acid modification in the activation region is at a cleavage site and comprises substituting Glu, Leu, Asp, Gly, or Ile for Arg 152 .
Claim 4
Dependent Claim 14 words
The polynucleotide molecule of claim 1, wherein the Factor VII is human Factor VII.
Claim 5
Dependent Claim 24 words
The polynucleotide molecule of claim 1, wherein the pre-pro peptide and gla domain are the pre-pro peptide and gla domain of human Factor VII.
Claim 6
Dependent Claim 24 words
The polynucleotide molecule of claim 1, wherein the modified Factor VII molecule encoded thereby competes with wild-type Factor VIIa for binding to tissue factor.
Claim 7
Dependent Claim 17 words
A mammalian cell line transfected with the polynucleotide molecule of claim 1, wherein said polynucleotide is DNA.
Claim 8
Dependent Claim 22 words
The transfected cell line of claim 6, wherein the cell line is a baby hamster kidney cell line or 293 cell line.
Claim 9
Dependent Claim 19 words
The transfected cell line of claim 7, wherein the cell line is BHK 570 having ATCC No. CRL 10314.

References Cited (Backward Citations)

US4775624A Cited
US4784950A Cited
WO1986006408A1 Cited
US4959318A Cited
EP0255771A1 Cited
EP0296413A2 Cited
EP0370036A1 Cited
US4994371A Cited
WO1989009612A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-02-21 1997-08-23 1998-02-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-02-21 2001-08-23 2002-02-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-02-21 2005-08-23 2006-02-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag